2015 ACVIM Forum Research Abstract Program

Three apparently healthy purpose bred cats were used in this 5-day pilot study. Based on previous studies, all cats were administered 0.625 mg (1/4 of commercially available tablet) PO BID. Following placement of an indwelling jugular catheter on day 0, initial PK data was obtained on day 1 following the first oral dose. Apixaban was then administered orally twice daily on days 1, 2, and 3 and peak and trough plasma concentrations determined. PD activity was assessed on days 1, 2, 3, and 4 by determining the effect of apixaban on factor Xa (FXa) activity using a commercially available assay. A single dose was administered on day 4, and plasma concentrations determined during a 12-hour washout period. All cats were monitored for side effects associated with multi-dose administration of the drug.